CODX ▼ -1.7% - Co-Diagnostics, Inc. $CODX CODX - Co-Diagnostics and ReadyGo Collaborate to Evaluate Blood-Based Molecular Testing at the Point of Need, Starting with Ebola Co-Diagnostics announced a collaboration with ReadyGo to evaluate blood-based molecular testing for point-of-care diagnostics, beginning with Ebola virus detection. The stock declined 1.7% despite the partnership news, suggesting investors may have been disappointed by the limited initial scope or other market factors. 16-SEP-2026 08:45 AM ET